GoalVest Advisory’s Adaptive Biotechnologies ADPT Stock Holding History

GoalVest Advisory’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.8K	Hold	830	–	–	﹤0.01%	314
2026 Q1	$11.5K	Hold	830	–	–	﹤0.01%	365
2025 Q4	$13.5K	Hold	830	–	–	﹤0.01%	396
2025 Q3	$12.4K	Hold	830	–	–	﹤0.01%	319
2025 Q2	$9.67K	Hold	830	–	–	﹤0.01%	309
2025 Q1	$6.17K	Hold	830	–	–	﹤0.01%	283
2024 Q4	$4.98K	Hold	830	–	–	﹤0.01%	302
2024 Q3	$4.25K	Hold	830	–	–	﹤0.01%	344
2024 Q2	$3K	Hold	830	–	–	﹤0.01%	295
2024 Q1	$2.66K	Hold	830	–	–	﹤0.01%	360
2023 Q4	$4.07K	Hold	830	–	–	﹤0.01%	296
2023 Q3	$4.52K	Hold	830	–	–	﹤0.01%	353
2023 Q2	$5.57K	Hold	830	–	–	﹤0.01%	293
2023 Q1	$7.33K	Hold	830	–	–	﹤0.01%	195
2022 Q4	$6.34K	Hold	830	–	–	﹤0.01%	197
2022 Q3	$6K	Hold	830	–	–	﹤0.01%	202
2022 Q2	$8K	Hold	830	–	–	0.01%	256
2022 Q1	$12K	Buy	+830	New	+$13.1K	0.01%	226
2021 Q2	$34K	Buy	+830	New	+$32.3K	0.02%	160

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

GoalVest Advisory's ADPT Position: Q2 2026 in Review

GoalVest Advisory held its Adaptive Biotechnologies (ADPT) position steady in Q2 2026 at 830 shares worth $17.8K. The position accounts for ﹤0.01% of the portfolio, ranked #314.

GoalVest Advisory first reported a position in ADPT in Q2 2021 and has held it in 19 quarters since. The position peaked at $34K in Q2 2021. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

GoalVest Advisory held 830 shares of Adaptive Biotechnologies worth $17.8K as of Q2 2026.
GoalVest Advisory left its Adaptive Biotechnologies share count unchanged in Q2 2026.
Adaptive Biotechnologies made up ﹤0.01% of GoalVest Advisory's portfolio in Q2 2026, its #314 holding.
GoalVest Advisory first reported a position in Adaptive Biotechnologies in Q2 2021 and has held it in 19 quarters since.
GoalVest Advisory's Adaptive Biotechnologies position peaked at $34K in Q2 2021.
301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on GoalVest Advisory's 13F filing for Q2 2026, filed 9 Jul 2026.